
    
      Primary hepatocellular carcinoma is one of the most common malignancies in China, ranking
      fourth in all malignant tumors and third in mortality.immunotherapy is considered to be one
      of the most promising means of human against cancer. This is a phase II clinical trial of
      single- center, The investigators plan to recruit for 90 patients with advanced liver
      cancer,and all patients are divided into three groups.one group will receive cryotherapy, one
      group will receive Non-intervention therapyï¼Œand the rest one will receive mixed liquor of
      activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.

      The result of this study was statistic and analysed with the record of Response Evaluation
      Criteria In Solid Tumors(RECIST1.1) evaluation standard.
    
  